Practice efficiency and total cost of care with bispecifics and CAR-T in relapsed/refractory diffuse large B-cell lymphoma: an institutional perspective¹

References

• Teras LR, DeSantis CE, Cerhan JR, et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016;66(6):443–459. doi:10.3322/caac.21357
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Surveillance Epidemiology, and End Results Program. Cancer stat facts: NHL—diffuse large B-cell lymphoma (DLBCL). Accessed September 22, 2023. Available from: https://seer.cancer.gov/statfacts/html/dlbcl.html
   Google Scholar
• Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800–1808. doi:10.1182/blood-2017-03-769620
   PubMed Web of Science ®Google Scholar
• Sehn LH, Salles G. Diffuse large B-cell lymphoma. N Engl J Med. 2021;384(9):842–858. doi:10.1056/NEJMra2027612
   PubMed Web of Science ®Google Scholar
• Johnston KJ, Jun M, Davies K, et al. Estimating the incidence of diffuse large B-cell lymphoma by line of therapy in the US using an epidemiological model to examine patient flow and treatment patterns. Poster presented at: American Managed Care Pharmacy Nexus National Meeting. National Harbor, MD, and virtual; October 11–14, 2022.
   Google Scholar
• Alderuccio JP, Sharman JP. ABCs of ADCs in management of relapsed/refractory diffuse large B-cell lymphoma. Blood Rev. 2022;56:100967. doi:10.1016/j.blre.2022.100967
   PubMed Web of Science ®Google Scholar
• Nedved A, Maddocks K, Nowakowski GS. Clinical treatment guidelines for tafasitamab plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. Oncologist. 2023;28(3):199–207. doi:10.1093/oncolo/oyac256
   PubMedGoogle Scholar
• Epkinly. Prescribing information. Genmab US, Inc; 2023. Accessed October 2, 2023. Available from: www.genmab-pi.com/prescribing-information/epkinly-pi.pdf
   Google Scholar
• Columvi. Prescribing information. Genentech, Inc; 2023. Accessed October 2, 2023. Available from: www.gene.com/download/pdf/columvi_prescribing.pdf
   Google Scholar
• Vokes EE. Amid healthcare workforce shortages, staffing guidance should ensure protection of individuals with cancer. American Society of Clinical Oncology (ASCO). Accessed September 25, 2023. Available from: https://old-prod.asco.org/news-initiatives/policy-news-analysis/amid-healthcare-workforce-shortages-staffing-guidance-should
   Google Scholar
• Bailey V. Hospitals increase recruitment strategies amid workforce shortages. Xtelligent Healthcare Media a division of TechTarget. Accessed September 25, 2023. Available from: https://revcycleintelligence.com/news/hospitals-increase-recruitment-strategies-amid-workforce-shortages
   Google Scholar
• Anderson KC, Landgren O, Arend RC, et al. Humanistic and economic impact of subcutaneous versus intravenous administration of oncology biologics. Future Oncol. 2019;15(28):3267–3281. doi:10.2217/fon-2019-0368
   PubMed Web of Science ®Google Scholar
• Epstein RS. Payer perspectives on intravenous versus subcutaneous administration of drugs. Clinicoecon Outcomes Res. 2021;13:801–807. doi:10.2147/ceor.S317687
   PubMed Web of Science ®Google Scholar
• McCloskey C, Ortega MT, Nair S, et al. A systematic review of time and resource use costs of subcutaneous versus intravenous administration of oncology biologics in a hospital setting. PharmacoEconomics - Open. 2023;7(1):3–36. doi:10.1007/s41669-022-00361-3
   PubMed Web of Science ®Google Scholar
• Stenger M. Subcutaneous vs. IV administration of medications and fluids in patients with cancer: U.S. vs Canadian cancer center methods. American Society of Clinical Oncology (ASCO). Accessed September 29, 2023. Available from: https://ascopost.com/news/march-2023/subcutaneous-vs.-iv-administration-of-medications-and-fluids-in-patients-with-cancer/
   Google Scholar
• Tang M, Abdelaal M, Lau J, et al. Subcutaneous vs intravenous administration of medications and fluids for patients with cancer in the US and Canada. JAMA Oncol. 2023;9(5):717–719. doi:10.1001/jamaoncol.2023.0239
   PubMed Web of Science ®Google Scholar
• Lugtenburg P, Avivi I, Berenschot H, et al. Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study. Haematologica. 2017;102(11):1913–1922. doi:10.3324/haematol.2017.173583
   PubMed Web of Science ®Google Scholar
• Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, Phase III, non-inferiority study. Lancet Oncol. 2011;12(5):431–440. doi:10.1016/s1470-2045(11)70081-x
   PubMed Web of Science ®Google Scholar
• Usmani SZ, Nahi H, Legiec W, et al. Final analysis of the Phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma. Haematologica. 2022;107(10):2408–2417. doi:10.3324/haematol.2021.279459
   PubMed Web of Science ®Google Scholar
• Yescarta. Prescribing information. Kite Pharma, Inc; 2023. Accessed January 11, 2024. Available from: www.gilead.com/-/media/files/pdfs/medicines/oncology/yescarta/yescarta-pi.pdf
   Google Scholar
• Centers for Medicare & Medicaid Services. Average sales price pricing files. April 2023. Accessed May 15, 2023. Available from: www.cms.gov/medicare/payment/all-fee-service-providers/medicare-part-b-drug-average-sales-price/asp-pricing-files
   Google Scholar
• Data.Medicaid.gov. National average drug acquisition cost. Accessed May 31, 2022. Available from: https://data.medicaid.gov/nadac
   Google Scholar
• Merative Micromedex. Merative Micromedex RED BOOK. Accessed April 2023. Available from: www.micromedexsolutions.com/home/dispatch
   Google Scholar
• Centers for Medicare & Medicaid Services. Addendum A and Addendum B updates. 2023. Accessed May 15, 2023. Available from: www.cms.gov/medicare/payment/prospective-payment-systems/hospital-outpatient/addendum-a-b-updates
   Google Scholar
• Abramson JS, Siddiqi T, Garcia J, et al. Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel-treated patients in the TRANSCEND NHL 001 trial. Blood Adv. 2021;5(6):1695–1705. doi:10.1182/bloodadvances.2020003531
   PubMed Web of Science ®Google Scholar
• Dasta JF, McLaughlin TP, Mody SH, et al. Daily cost of an intensive care unit day: the contribution of mechanical ventilation. Crit Care Med. 2005;33(6):1266–1271. doi:10.1097/01.ccm.0000164543.14619.00
   PubMed Web of Science ®Google Scholar
• Kaiser Family Foundation. Hospital adjusted expenses per inpatient day. 2021. Accessed May 15, 2023. Available from: www.kff.org/health-costs/state-indicator/expenses-per-inpatient-day/?currentTimeframe=0&sortModel=%7B%22colId%22:%22Location%22,%22sort%22:%22asc%22%7D
   Google Scholar
• U.S. Bureau of Labor Statistics. Occupational employment and wage statistics. May 2022. Accessed May 15, 2023. Available from: www.bls.gov/oes/current/oes_stru.htm
   Google Scholar
• U.S. Bureau of Labor Statistics. Data Tools. 2022. Accessed May 24, 2023. Available from: www.bls.gov/data/home.htm
   Google Scholar
• Centers for Medicare & Medicaid Services. Clinical laboratory fee schedule files. 2023. Accessed May 15, 2023. Available from: www.cms.gov/medicare/payment/fee-schedules/clinical-laboratory-fee-schedule-clfs/files
   Google Scholar
• American Society for Health Care Risk Management. Underpayment by Medicare and Medicaid fact sheet. January 2020. Accessed May 31, 2022. Available from: www.ashrm.org/node/5075
   Google Scholar
• Pierce CA, Baker JJ. A nursing process model: quantifying infusion therapy resource consumption. J Infus Nurs. 2004;27(4):232–244. doi:10.1097/00129804-200407000-00008
   PubMedGoogle Scholar
• Harvey MJ, Zhong Y, Morris E, et al. Assessing the transition from intravenous to subcutaneous delivery of rituximab: benefits for payers, health care professionals, and patients with lymphoma. PLOS ONE. 2022;17(1):e0261336. doi:10.1371/journal.pone.0261336
   PubMed Web of Science ®Google Scholar
• Shinder GA, Paradis PE, Posman M, et al. Patient and work flow and costs associated with staff time and facility usage at a comprehensive cancer centre in Quebec, Canada—a time and motion study. BMC Health Serv Res. 2012;12:370. doi:10.1186/1472-6963-12-370
   PubMed Web of Science ®Google Scholar
• Burcombe R, Chan S, Smiock R, et al. Subcutaneous trastuzumab (Herceptin®): a UK time and motion study in comparison with intravenous formulation for the treatment of patients with HER2-positive early breast cancer. Adv Breast Cancer Res. 2013;2:133–140.
   Google Scholar
• North RT, Harvey VJ, Cox LC, et al. Medical resource utilization for administration of trastuzumab in a New Zealand oncology outpatient setting: a time and motion study. Clinicoecon Outcomes Res. 2015;7:423–430. doi:10.2147/ceor.S85599
   PubMed Web of Science ®Google Scholar
• De Cock E, Kritikou P, Sandoval M, et al. Time savings with rituximab subcutaneous injection versus rituximab intravenous infusion: a time and motion study in eight countries. PLOS ONE. 2016;11(6):e0157957. doi:10.1371/journal.pone.0157957
   PubMed Web of Science ®Google Scholar
• Rule S, Collins GP, Samanta K. Subcutaneous vs. intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom. J Med Econ. 2014;17(7):459–468. doi:10.3111/13696998.2014.914033
   PubMedGoogle Scholar
• Slavcev M, Spinelli A, Absalon E, et al. Results of a time and motion survey regarding subcutaneous versus intravenous administration of daratumumab in patients with relapsed or refractory multiple myeloma. Clinicoecon Outcomes Res. 2021;13:465–473. doi:10.2147/ceor.S302682
   PubMed Web of Science ®Google Scholar
• Drill E, Qiu A, Shapouri S, et al. Real-world assessment of patient care and practice efficiency with the introduction of subcutaneous rituximab. Oncology (Williston Park). 2021;35(12):804–811. doi:10.46883/2021.25920935
   PubMed Web of Science ®Google Scholar
• Barbee MS, Harvey RD, Lonial S, et al. Subcutaneous versus intravenous bortezomib:efficiency practice variables and patient preferences. Ann Pharmacother. 2013;47(9):1136–1142. doi:10.1177/1060028013503122
   PubMed Web of Science ®Google Scholar
• Rojas L, Muñiz S, Medina L, et al. Cost-minimization analysis of subcutaneous versus intravenous trastuzumab administration in Chilean patients with HER2-positive early breast cancer. PLOS ONE. 2020;15(2):e0227961. doi:10.1371/journal.pone.0227961
   PubMed Web of Science ®Google Scholar
• Rahib L, Wehner MR, Matrisian LM, et al. Estimated projection of US cancer incidence and death to 2040. JAMA Netw Open. 2021;4(4):e214708. doi:10.1001/jamanetworkopen.2021.4708
   PubMed Web of Science ®Google Scholar
• Takvorian SU, Balogh E, Nass S, et al. Developing and sustaining an effective and resilient oncology careforce: opportunities for action. J Natl Cancer Inst. 2020;112(7):663–670. doi:10.1093/jnci/djz239
   PubMedGoogle Scholar
• Shulman LN, Sheldon LK, Benz EJ. The future of cancer care in the United States—overcoming workforce capacity limitations. JAMA Oncol. 2020;6(3):327–328. doi:10.1001/jamaoncol.2019.5358
   PubMed Web of Science ®Google Scholar
• Yang W, Williams JH, Hogan PF, et al. Projected supply of and demand for oncologists and radiation oncologists through 2025: an aging, better-insured population will result in shortage. J Oncol Pract. 2014;10(1):39–45. doi:10.1200/jop.2013.001319
   PubMedGoogle Scholar
• Falchi L, Carlo-Stella C, Morschhauser F, et al. Dexamethasone is associated with a lower incidence and severity of cytokine release syndrome compared with other corticosteroid regimens when given as premedication for glofitamab monotherapy in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Blood. 2023;142(Suppl. 1):3130. doi:10.1182/blood-2023-173949
   Google Scholar
• Vose JM, Feldman T, Chamuleau M, et al. Mitigating the risk of cytokine release syndrome (CRS): preliminary results from a DLBCL cohort of Epcore NHL-1. Blood. 2023;142(Suppl. 1):1729. doi:10.1182/blood-2023-180333
   Google Scholar
• Portugese AJ, Albittar A, Huang JJ, et al. Real-world comparison of lisocabtagene maraleucel (liso-cel) and axicabtagene ciloleucel (axi-cel): efficacy & toxicity. Transplant Cell Ther. 2024;30(2):S192.
   Google Scholar